Sequana Medical NV

Pioneer in treating drug-resistant fluid overload, a serious and frequent clinical complication in patients with liver disease, heart failure and cancer.

[Sequana Medical NV @SequanaMed]

In a recent interview, our CEO Ian Crosbie discusses the alfapump System, the POSEIDON study, and what it means to bring a modern treatment to patients with refractory ascites. Read the full interview: https://t.co/t3461WMdov
ISI: https://t.co/1wpa7eshe4 #LiverDisease #Ascites

[Sequana Medical NV @SequanaMed]

Did you know @PennMedicine offers the alfapump System at their dedicated Ascites Clinic? Learn more about this treatment option for patients with recurrent or refractory ascites due to liver cirrhosis: https://t.co/z2I7fhzQXw

ISI: https://t.co/1wpa7eshe4

#LiverDisease #Ascites

[Sequana Medical NV @SequanaMed]

We announced post-hoc POSEIDON study data on recompensation of decompensated cirrhosis and long-term resolution of ascites at #EASL2026!

See the news here: https://t.co/ntUmfPkwmS

#Ascites #Hepatology

[Sequana Medical NV @SequanaMed]

The alfapump requires just one thing from patients each day: a 20-minute wireless recharge.

Just like charging a phone.

https://t.co/UHul5Cs7hY

ISI: https://t.co/1wpa7eshe4

[Sequana Medical NV @SequanaMed]

The pivotal POSEIDON study, published in the Am J Gastroenterology, found that the alfapump significantly reduced therapeutic paracentesis and gave patients an average of 10 additional good health days per month.

https://t.co/pPiImwozoG

ISI: https://t.co/1wpa7eshe4

[Sequana Medical NV @SequanaMed]

Obesity is changing the face of liver cirrhosis and shifting attitudes toward the standard of care.

Hear our CEO on the Empowered Patient Podcast discuss what that means for patients with ascites.

https://t.co/bkz1j2tdR6

#LiverDisease #MASH #Ascites #Podcast

[Sequana Medical NV @SequanaMed]

May is #HepatitisAwarenessMonth.

Untreated hepatitis can lead to cirrhosis and liver failure, conditions we know all too well at Sequana. We stand with the liver disease community in encouraging testing and early intervention.

https://t.co/uAV4nQtJH6

#HepAware #LiverDisease

[Sequana Medical NV @SequanaMed]

The alfapump automatically moves fluid from the abdomen to the bladder. No needles, no external tubes, no repeated hospital visits.

Just a 30-minute daily wireless recharge and regular reporting on pump performance to the treating physician.

https://t.co/ms5xFJGkPk

[Sequana Medical NV @SequanaMed]

@WorldLiverDay's theme, #SolidHabitsStrongLiver, highlights the importance of taking control of #liverhealth to prevent serious complications. At Sequana, we're proud to champion liver health and improve outcomes for patients with advanced liver disease. https://t.co/ZHDxoB8vqt

[Sequana Medical NV @SequanaMed]

In case you missed it, our CEO, Ian Crosbie, joined the Empowered Patient Podcast to discuss life with recurrent or refractory ascites and why patients deserve better options.

🎧 https://t.co/bkz1j2tdR6

#LiverDisease #Ascites #Podcast

[Sequana Medical NV @SequanaMed]

The POSEIDON study followed patients with recurrent or refractory ascites across 18 U.S. and Canadian centers over two years.

The findings: virtual elimination of therapeutic paracentesis and meaningful quality of life improvements.

https://t.co/GJltuxQ8A6

#LiverDisease

[Sequana Medical NV @SequanaMed]

We’re heading to #SIR2026 in Toronto tomorrow!

Visit us at Booth #1525 to learn how the alfapump is offering a new treatment option for patients with recurrent or refractory ascites due to liver cirrhosis.

@SIRspecialists

https://t.co/Tlx5RTWfrM

[Sequana Medical NV @SequanaMed]

For patients with recurrent or refractory #ascites due to liver #cirrhosis, daily life can be difficult.

Fluid accumulation in the abdomen causes fatigue, shortness of breath, and difficulty eating and sleeping, leading to withdrawal from everyday life.

https://t.co/jdlWDAUXWu

[Sequana Medical NV @SequanaMed]

Science has the power to transform lives, including for patients with recurrent or refractory #ascites who've faced endless procedures.

This #WorldHealthDay, we #StandWithScience to drive innovation that aims to change the standard of care for these patients.

#LiverDisease

[Sequana Medical NV @SequanaMed]

Thank you @medtechonline for covering our U.S. progress with the alfapump System!

Implants completed at 5 leading centers since launch — with 20 more institutions in the pipeline.

Read more: https://t.co/YsrOL0GtIQ

#LiverDisease #Ascites #alfapump

[Sequana Medical NV @SequanaMed]

On National Doctors' Day we celebrate the hepatologists, gastroenterologists and interventional radiologists advancing care for patients with liver disease.

Your commitment to innovation and excellence makes all the difference.

#NationalDoctorsDay #LiverDisease

[Sequana Medical NV @SequanaMed]

We’ll be at the VFB Happening in Belgium!

Come visit our booth and learn more about Sequana Medical and the alfapump System for patients with refractory or recurrent ascites due to liver cirrhosis.

Our CEO Ian Crosbie will present at the Speaker Corner at 13:10.

#VFBHappening

[Sequana Medical NV @SequanaMed]

The alfapump System is a battery-powered fully implantable pump that automatically removes ascites fluid from the abdomen to the bladder, where it's eliminated naturally.

Learn more: https://t.co/TqhHLfXYLM

#LiverDisease #Ascites

[Sequana Medical NV @SequanaMed]

MASH is one of the fastest-growing causes of liver cirrhosis in the U.S., closely linked to diabetes and obesity.
This ‘silent disease’ is difficult to diagnose early, and can progress to cirrhosis and complications like ascites.

#LiverDisease #Ascites
https://www.sequanamedical

[Sequana Medical NV @SequanaMed]

Our CEO Ian Crosbie joined the Empowered Patient Podcast to discuss liver disease, the challenges of refractory liver ascites, and how the alfapump System is changing treatment.

Listen here: https://t.co/bkz1j2tdR6